New study to test anthrax treatment in bioterror attack scenario
NCT ID NCT02177721
First seen Feb 06, 2026 · Last updated May 13, 2026 · Updated 12 times
Summary
This study will look at how well the drug raxibacumab works and how safe it is for people who get sick with inhalational anthrax after a large-scale exposure, like a bioterrorist attack. About 100 people of all ages, including pregnant women, who receive the drug from the national stockpile can join. The goal is to learn if the drug helps people survive and to gather information to improve future treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTIONS, BACTERIAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.